期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 51, 期 15, 页码 4632-4640出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm800566m
关键词
-
Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N-4-(2,3-dimethyl-2H-indazol-6-yl)-N-4-methyl-N-2-(4-methyl-3-sulfonamidophenyl)-2,4-pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据